Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein
© Bernis et al. 2015
Received: 6 November 2015
Accepted: 6 November 2015
Published: 26 November 2015
Parkinson’s disease (PD) and multiple system atrophy (MSA) are neurodegenerative diseases that are characterized by the intracellular accumulation of alpha-synuclein containing aggregates. Recent increasing evidence suggests that Parkinson’s disease and MSA pathology spread throughout the nervous system in a spatiotemporal fashion, possibly by prion-like propagation of alpha-synuclein positive aggregates between synaptically connected areas. Concurrently, intracerebral injection of pathological alpha-synuclein into transgenic mice overexpressing human wild-type alpha-synuclein, or human alpha-synuclein with the familial A53T mutation, or into wild-type mice causes spreading of alpha-synuclein pathology in the CNS. Considering that wild-type mice naturally also express a threonine at codon 53 of alpha-synuclein, it has remained unclear whether human wild-type alpha-synuclein alone, in the absence of endogenously expressed mouse alpha-synuclein, would support a similar propagation of alpha-synuclein pathology in vivo.
Here we show that brain extracts from two patients with MSA and two patients with probable incidental Lewy body disease (iLBD) but not phosphate-buffered saline induce prion-like spreading of pathological alpha-synuclein after intrastriatal injection into mice expressing human wild-type alpha-synuclein. Mice were sacrificed at 3, 6, and 9 months post injection and analyzed neuropathologically and biochemically. Mice injected with brain extracts from patients with MSA or probable iLBD both accumulated intraneuronal inclusion bodies, which stained positive for phosphorylated alpha-synuclein and appeared predominantly within the injected brain hemisphere after 6 months. After 9 months these intraneuronal inclusion bodies had spread to the contralateral hemisphere and more rostral and caudal areas. Biochemical analysis showed that brains of mice injected with brain extracts from patients with MSA and probable iLBD contained hyperphosphorylated alpha-synuclein that also seeded aggregation of recombinant human wild-type alpha-synuclein in a Thioflavin T binding assay.
Our results indicate that human wild-type alpha-synuclein supports the prion-like spreading of alpha-synuclein pathology in the absence of endogenously expressed mouse alpha-synuclein in vivo.
KeywordsParkinson’s disease Multiple system atrophy Incidental Lewy body disease alpha-synuclein Synucleinopathy Prion-like
Parkinson’s disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB) are part of a spectrum of neurodegenerative disorders characterized by accumulation of misfolded alpha-synuclein, preferentially in cells of the nervous system, and are therefore often conceptualized as synucleinopathies [52, 53, 60]. Missense mutations in alpha-synuclein, such as A53T, or duplications and triplications of the SNCA gene encoding alpha-synuclein have been linked to familial PD and suggest that in synucleinopathies alpha-synuclein itself can become pathogenic [4, 15, 20, 37, 51, 62]. This has also raised interest in the putative relationship between posttranslational modifications of alpha-synuclein, such as hyperphosphorylation at S129, and its misfolding and deposition in disease [11, 49].
The seminal neuropathological analyses of Braak and co-workers suggest that the regional distribution of pathological alpha-synuclein in the brains of patients is progressive and can be classified into stages [3, 27]. Although this concept is not undisputed , aggregation of alpha-synuclein in embryonic dopamine neurons grafted into the striatum of PD patients for therapy spurred the hypothesis that misfolded alpha-synuclein may indeed spread between cells and seed aggregation of normal alpha-synuclein [17, 25]. Subsequent studies in cultured neurons and rodents showed that exogenous pathological alpha-synuclein can seed misfolding and aggregation of native alpha-synuclein and that pathological alpha-synuclein may propagate in a prion-like manner within the nervous system [8, 18, 24, 28, 29, 31, 33, 41, 42, 47, 58, 59, 61]. In most of the above studies either synthetic alpha-synuclein fibrils generated in vitro or transgenic M83-mice overexpressing alpha-synuclein with the familial A53T mutation, or wild-type mice or rats naturally expressing a threonine at codon 53 were used for inoculation experiments. While propagation of alpha-synuclein pathology can also be induced in M20-mice overexpressing human wild-type alpha-synuclein in the presence of endogenously expressed mouse alpha-synuclein [45, 46], it remains unresolved whether human wild-type alpha-synuclein by itself, in the absence of endogenously expressed mouse alpha-synuclein, would support prion-like spreading of pathological alpha-synuclein in mice. Moreover, it is unresolved whether endogenously expressed mouse alpha-synuclein may actually hamper misfolding and spreading of transgenically expressed human alpha-synuclein. In the field of prion diseases, transgenic mice expressing human prion protein in the presence of endogenously expressed mouse prion protein are resistant to infection with human prions from Creutzfeldt-Jakob disease patients, and only become susceptible to human prions when endogenous expression of the mouse prion protein is ablated [56, 57]. We therefore investigated the fate of mice expressing human wild-type alpha-synuclein on a knockout background for mouse alpha-synuclein after intrastriatal injection of brain extracts from patients with MSA and probable incidental Lewy body disease (iLBD) [14, 21]. Our results suggest that human wild-type alpha-synuclein indeed supports prion-like propagation of pathological alpha-synuclein from the brains of MSA patients. Moreover, our results suggest that not only MSA brains but also brains of individuals with iLBD contain misfolded alpha-synuclein species that can induce prion-like spreading of misfolded alpha-synuclein in mice.
Materials and methods
Preparation of brain extracts for injections
Characteristics of MSA and iLBD cases used for inoculation experiments
Age at death (years)
Postmortem delay time (h)
Alpha-synuclein concentration in the sarkosyl-insoluble fraction (ng/ml)
Six- to eight-week-old FVB;129S6-Snca tm1Nbm Tg(SNCA)1Nbm/J mice (short: Tg(SNCA)1Nbm/J mice, The Jackson Laboratory) were anaesthetized with isoflurane and stereotaxically injected with 30 μl of cortical brain extract from MSA or probable iLBD cases or PBS into the left striatum (coordinates: +0.2 mm relative to the bregma, +2.0 mm relative to the midline, 2.6 mm below the dura) using a 27-gauge disposable hypodermic syringe. After recovery from surgery, animals were monitored daily for health and three times weekly for signs of neurologic illness such as reduced grooming, ataxia, tremor, bradykinesia, akinesia, lethargy, circling, tail rigidity, paraparesis, paralysis, kyphosis, and more. At 3, 6, and 9 months post injection the mice were sacrificed by overdose with ketamine/xylazine and then transcardially perfused with 0.9 % saline followed by 10 % formalin neutral buffer solution (Sigma). Brains were fixed overnight with 1 % formalin neutral buffer solution for immunohistochemistry. For biochemical analysis, brains were snap-frozen on dry ice and stored at −80 °C. All animal studies were approved by the animal protection committee of the North Rhine-Westphalia State Environment Agency (LANUV).
For paraffin sections brains fixed in 1 % formalin were dehydrated and infiltrated with paraffin using standard procedures. Brains were cut into 8-μm-thick coronal sections, mounted on glass slides, deparaffinized, and hydrated through a series of graded ethanol solutions followed by antigen-retrieval treatment for 10 min (Additional file 1). Endogenous tissue peroxide was inhibited by incubating slides in 3 % hydrogen peroxide solution for 30 min. Slides were then blocked with 30 % (v/v) normal goat serum, 1 % (v/v) bovine serum albumin, and 0.5 % Triton X-100 for 1 h and then incubated with primary antibody overnight at 4 °C (Additional file 1). Bound antibody was detected using a Vectastain ABC kit (Vector Laboratories) and visualized using DAB (3-3’-diaminobenzidine). Slides were counterstained with Hematoxylin QS (Vector Laboratories) and coverslipped with Vectamount AQ (Vector Laboratories). All slides were scanned using an Axio Scan.Z1 scanner and ZEN lite software (Carl Zeiss). For cryosections brains were fixed in 4 % formalin and protected in 30 % sucrose solution in PBS using standard procedures. Brains were cut into 25-μm-thick coronal sections, followed by antigen-retrieval treatment (Additional file 1). Staining was performed on free-floating sections. Brain sections were blocked with 10 % (v/v) normal goat serum and 0.3 % Triton X-100 for 1 h and incubated with primary antibody overnight as above. Bound antibody was detected using a Liquid DAB+ Substrate Chromagen System (Dako). The sections were mounted on slides, counterstained, coverslipped, and analyzed as above.
Paraffin-embedded tissues were cut into 8-μm-thick coronal sections, deparaffinized, and hydrated followed by antigen retrieval treatment for 10 min (Additional file 1). The tissues were incubated in 1 mM CuSO4 in 50 mM ammonium acetate buffer at pH 5. Slides were blocked with 30 % (v/v) normal goat serum, 1 % (v/v) BSA, and 0.5 % Triton X-100 for 1 h and then incubated with primary antibody overnight at 4 °C (Additional file 1). After washing twice with PBS containing 0.25 % (v/v) Triton X-100 and once with PBS, sections were incubated with secondary antibodies conjugated to Alexa Fluor 488- or Alexa Fluor 568-conjugated goat anti-mouse or rabbit antibodies (Thermo Fisher Scientific). Sections were stained with DAPI (4’,6-diamidino-2-phenylindole; Thermo Fisher Scientific), coverslipped with Fluoromount (Sigma), and visualized using an LSM700 confocal microscope (Carl Zeiss).
Mouse brains were fractionated as described above for the preparation of human brain extracts for injections. However, the sarkosyl-soluble supernatant and the sarkosyl-insoluble pellet were taken up in Ca2+- and Mg2+-free PBS (pH 7.4) with protease and phosphatase inhibitors (cOmplete and PhosSTOP, Roche Diagnostics) and benzonase nuclease (Sigma) for the removal of nucleic acid. Protein concentrations were determined with the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Samples were taken up in 1× NuPAGE loading buffer, boiled for 10 min, and then loaded onto 4-12 % NuPAGE gels (Thermo Fisher Scientific). Insoluble fractions of human brains were prepared as described above for injections. However, the sarkosyl-insoluble pellet was taken up in 500 μl of 30 mM Tris–HCl (pH 7.4) and sonicated. A mouse monoclonal anti-alpha-synuclein antibody (clone 42, BD Biosciences) was incubated at a 1:20 dilution with 50 μl of Dynabeads protein G slurry (Thermo Fisher Scientific) for 30 min at room temperature. Diluted insoluble fractions were incubated with the immune complex for 1 h at room temperature. The resultant pellet (P1) was washed three times with wash buffer and eluted with 20 μl of elution buffer and 10 μl of 4× loading buffer. The supernatant was subjected to a second immunoprecipitation step with a fresh immune complex overnight at 4 °C. The resultant pellet was washed three times with wash buffer. Finally, immunoprecipitated alpha-synuclein was eluted in 20 μl of elution buffer and 10 μl of 4× loading buffer, combined with the first pellet (P1), and boiled for 10 min. Protein was resolved on 4-12 % NuPAGE gels. SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) was performed using a MOPS buffer system (Thermo Fisher Scientific), and gels were subsequently transferred to PVDF membranes using a wet blotting system. Blots were then cross-linked with 0.4 % (v/v) paraformaldehyde in PBS for 30 min. Membranes were blocked for 1 h at room temperature with 5 % (w/v) bovine serum albumin in Tris-buffered saline containing 0.05 % (v/v) Tween 20 and then incubated with primary antibody overnight at 4 °C (Additional file 1). Blots were developed with IRDye 680- or IRDye 800-conjugated goat anti-mouse or goat anti-rabbit secondary antibodies (LI-COR Biosciences), and imaged with an Odyssey infrared imaging system (LI-COR Biosciences).
Sequential extraction was performed as previously described . Briefly, 10 % (w/v) brain homogenates prepared in Ca2+- and Mg2+-free PBS (pH 7.4) were shifted to high-salt (HS) buffer by the addition of NaCl to a final concentration of 750 mM and EDTA to a final concentration of 5 mM. One hundred microliters of brain homogenate in HS buffer were sonicated for 5 min using a water-bath sonicator and then centrifuged at 100,000 × g for 30 min at 4 °C. The pellet was then resuspended by pipetting in 100 μl of HS-T buffer [50 mM Tris–HCl (pH 7.5), 750 mM NaCl, 5 mM EDTA, 1 % (v/v) Triton X-100]. Samples were then sonicated and centrifuged at 100,000 × g for 30 min at 4 °C. Cycles of extraction, sonication, and centrifugation were repeated using the following buffers in sequence: RIPA buffer [50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1 % (v/v) Nonidet P-40, 0.5 % (w/v) sodium deoxycholate, 0.1 % (w/v) SDS] and SDS buffer [50 mM Tris–HCl (pH 7.5), 2 % (w/v) SDS]. Protease and phosphatase inhibitors were added to buffers before use. For each extraction step, a 60 μl sample of the supernatant was removed, adjusted to 1× NuPAGE loading buffer by the addition of 20 μl of 4× loading buffer and then boiled. Samples from each of the extraction steps were analyzed by immunoblotting as described before.
To determine alpha-synuclein expression in different brain regions of non-transgenic and Tg(SNCA)1Nbm/J mice, tissue from these regions was collected and homogenized in Ca2+- and Mg2+-free PBS (pH 7.4) to yield a 10 % (w/v) homogenate to which sarkosyl was added to yield a final concentration of 2 % (v/v) sarkosyl. Protein concentrations were determined using the Pierce BCA Protein Assay Kit, and samples of 5 μg total protein were separated on 4-12 % NuPAGE gels as described above.
Production and purification of recombinant alpha-synuclein
Alpha-synuclein cDNA was transferred from plasmid pMA-T-SCNA (Thermo Fisher Scientific) as an NheI-XhoI fragment into the expression plasmid pET28a(+) (Merck) yielding pET28a(+)-aSWT. The E. coli strain BL21(DE3) (Merck) was transformed with sequence verified pET28a(+)-aSWT and individual clones were screened for production of recombinant protein following induction with isopropyl-D-thiogalactopyranoside (IPTG, Sigma). Expression with this system leads to translocation of the 6His-alpha synuclein wild-type protein into the periplasmatic space. For protein production, E. coli cells were grown at 37 °C in 1 L LB media containing ampicillin and 1 % glucose to an OD600 of approximately 0.5, induced with 1 mM IPTG and grown for 5 h at 37 °C. The periplasmatic material was released into buffer using an osmotic shock protocol . Briefly, cells were pelleted by centrifugation at 6,000 × g for 15 min. The pellet was resuspended in a 35 % sucrose solution in 2 mM EDTA and 30 mM Tris–HCl (pH 7.2) and incubated with shaking at room temperature for 15 min. The cells were again harvested and resuspended in ice-cold water containing 5 mM MgSO4. The periplasmatic material was boiled for 20 min and then centrifuged for 30 min at 21,000 × g. 6His-alpha-synuclein was purified from the supernatant by Ni-NTA affinity chromatography using 20 mM sodium phosphate buffer, pH 7.4, 500 mM NaCl, and 10 mM imidazole as binding buffer and 20 mM sodium phosphate buffer (pH 7.4), 500 mM NaCl, and 500 mM imidazole as elution buffer on an ÄKTA pure chromatography system (GE Healthcare). The protein was dialyzed against 150 mM NaCl in 20 mM Tris–HCl (pH 7.2), and used for seeding assays.
Thioflavin T binding assay
Kinetic seeding aggregation assays were performed by incubating his-tagged monomeric alpha-synuclein (50 μM) in low-binding black 96-well plates (Corning) at 37 °C in TBS with 20 μM Thioflavin T (Sigma) and 0.05 % (w/v) sodium azide (Sigma). Glass balls with 2 mm in diameter (Hecht) were distributed into each well of the 96-well plate to increase agitation. Seeds, 4 μl of a 10 % brain homogenate, were sonicated for 15 min in in a TK-52 water bath sonifier (Bandelin) before adding to the samples. Fluorescence (440 nm excitation, 485 nm emission, top read) was measured in an Envision multilabel reader (Perkin Elmer) at 15 min intervals preceded by 45 s shaking at 300 rpm in orbital mode with a 2 mm diameter.
Summary of intrastriatal injections into Tg(SNCA)1Nbm/J mice
Number of mice injected
Time post-injection when the animal was euthanized (months)
Spread of pathology
30 μl PBS
30 μl PBS
30 μl PBS
30 μl MSA1 BE
30 μl MSA1 BE
30 μl MSA1 BE
30 μl MSA2 BE
30 μl MSA2 BE
30 μl MSA2 BE
30 μl iLBD1 BE
30 μl iLBD1 BE
30 μl iLBD1 BE
30 μl iLBD2 BE
30 μl iLBD2 BE
30 μl iLBD2 BE
Next, we investigated whether Tg(SNCA)1Nbm/J mice injected with cortical extracts from MSA or probable iLBD cases or PBS had developed any form of gliosis in their CNS at 9 months post injection. Staining with antibodies against glial fibrillary acidic protein (GFAP) revealed exclusively a mild reactive astrocytic gliosis in the hippocampus of all mice but nowhere else in the CNS, regardless if they had been injected with cortical extracts from MSA or iLBD cases or PBS (Additional file 6). This suggests that this transgenic mouse line has an intrinsic property to develop mild hippocampal astrocytic gliosis with age. Staining with antibodies against allograft inflammatory factor 1 (also known as Iba1) did not reveal augmented activation of microglia in mice injected with human brain extracts in comparison to mice injected only with PBS (Additional file 7). Thus, the injections did not cause any enhanced gliosis in Tg(SNCA)1Nbm/J mice at 9 months post injection.
In this study we have shown that intrastriatal injection of cortical brain extracts from MSA and iLBD cases into mice expressing human wild-type alpha-synuclein but not endogenous mouse alpha-synuclein causes the appearance and prion-like spreading of inclusion bodies that contain phosphorylated alpha-synuclein in vivo. Prion-like spreading of alpha-synuclein containing aggregates has been shown in M83-mice overexpressing human alpha-synuclein with the A53T-mutation and in wild-type mice after injection with synthetic alpha-synuclein fibrils made from recombinant protein [28, 29, 31]. Accumulation of phosphorylated alpha-synuclein has also been shown after inoculation of alpha-synuclein fibrils in M20-mice overexpressing human alpha-synuclein in the presence of endogenously expressed mouse alpha-synuclein [12, 46]. Recently, one study showed that brain homogenates from MSA patients caused disease with incubation times of 143 ± 16 and 106 ± 11 days when injected in M83+/−-mice . However, injection of wild-type mice with brain extracts from patients with dementia with Lewy bodies only led to deposits of alpha-synuclein in 50 % of the injected mice at 15 months post injection that was mostly restricted to the injected hemisphere . Although human and mouse alpha-synuclein can cross-seed each other, it is possible that this inefficient transmission was due to a species barrier as it is often observed in prion transmission studies where differences in the primary structure between the endogenously expressed prion protein and that of the infectious prion protein in the inoculum can hamper cross-species transmission . Moreover, prion transmission studies to transgenic mice expressing the human prion protein have shown that mice only became susceptible to infection with human prions from Creutzfeldt-Jakob patients when expression of the mouse prion protein was ablated and only the human prion protein was expressed [56, 57]. In this study, all Tg(SNCA)1Nbm/J mice injected with patient brain extracts developed synucleinopathy that efficiently spread to the contralateral hemisphere within 9 months post injection suggesting that sequence identity between the alpha-synuclein seeds from human brain extracts and human wild-type alpha-synuclein expressed in these mice and possibly also the lack of endogenously expressed mouse alpha-synuclein facilitated the prion-like spread. Interestingly, the lack of endogenously expressed mouse alpha-synuclein did not affect incubation times in M83+/−-mice after inoculation with MSA brain homogenates . Our qualitative analysis showed widespread localization of phosphorylated alpha-synuclein in the CNS, including the cortex, of Tg(SNCA)1Nbm/J mice after injection with patient brain extracts. In spontaneously diseased M83-mice, there is some accumulation of phosphorylated-alpha-synuclein in the cortex but more in the cerebellum, brain stem, especially the mesencephalon, and spinal cord [12, 29]. The distribution of alpha-synuclein pathology is however different in M83-, M20-, and wild-type mice that have been injected with recombinant alpha-synuclein fibrils and in these cases can more strongly involve the cortex [28, 48]. Differences in the localization of phosphorylated alpha-synuclein may among other reasons arise from the type of material injected, in our case patient brain extracts versus recombinant fibrils of alpha-synuclein in the other mouse models. While it is still a matter of investigation whether different strains of alpha-synuclein exist [36, 39], in prion diseases, the pathology observed is dependent on the expression profile of the prion protein and the type of prion strain inoculated . In analogy, differences in the expression profile of alpha-synuclein could also affect the accumulation pattern of alpha-synuclein pathology. Notably, alpha-synuclein expression is driven in Tg(SNCA)1Nbm/J mice from the human SNCA promoter and in M83- and M20-mice from the hamster Prnp promoter.
Interestingly, punctate aggregates of phosphorylated alpha-synuclein in the brains of Tg(SNCA)1Nbm/J mice injected with brains extracts from patients with MSA or iLBD colocalized with ubiquitin and p62 as has been observed in earlier transmission studies to other mouse models of synucleinopathies [31, 45–48]. In contrast to another study in which wild-type mice were injected with synthetic alpha-synuclein fibrils and accumulated dot-like inclusions of phosphorylated microtubule-associated protein tau and TAR DNA-binding protein-43 (also known as TDP-43), we did not observe accumulation of these proteins in the brains of Tg(SNCA)1Nbm/J mice at 9 months post injection of human brain extracts, which may reflect differences of injected material .
In contrast to the mouse models described above where alpha-synuclein pathology was first observed between 2 and 4 months post injection based on the model and alpha-synuclein deposits were insoluble in detergent, we detected alpha-synuclein pathology only at 6 months post injection in our animal model. Moreover, in our model the phosphorylated alpha-synuclein component in the inclusion bodies was soluble in sarkosyl suggesting that the inclusion bodies in injected Tg(SNCA)1Nbm/J mice represent an early state of synucleinopathy. We chose to terminate these experiments at 9 months post injection and it is possible that a longer incubation time after injection of MSA or iLBD brain extracts may have resulted in more severe pathology with sarkosyl-insoluble alpha-synuclein aggregates and clinical signs as observed in M83+/−-mice injected with brain homogenate from MSA patients  or wild-type mice injected with synthetic alpha-synuclein fibrils [28, 31]. A recent study also shows that intracerebral injections of 30 μl of a 1 % brain homogenate from two MSA patients did not cause visible signs of disease in Tg(SNCA)1Nbm/J mice within a year . Alternatively, expression levels of wild-type human alpha-synuclein may be too low in Tg(SNCA)1Nbm/J mice to allow for a more severe type of synucleinopathy to develop. Cortical protein levels of the A53T-mutant of human alpha-synuclein in M83+/−-mice are 3.3 ± 0.5-fold and that of M20+/−-mice 5.6 ± 0.7-fold above that of mouse alpha-synuclein expressed in wild-type mice . Moreover, M83+/−- and M20+/−-mice still express endogenous mouse alpha-synuclein, which could contribute to the changes observed in those mice considering that prion-like propagation of alpha-synuclein aggregates can be induced in wild-type mice [28, 31]. Also, human wild-type alpha-synuclein has a much lower propensity to aggregate than human alpha-synuclein carrying the A53T mutation, which is associated with familial PD, or than murine wild-type alpha-synuclein, which naturally carries threonine at this position [37, 44]. While this paper was in preparation another study reported induction of alpha-synuclein pathology in the brains of wild-type mice and macaques after injection with Lewy body extracts from brains of patients with PD . Similar to our observations Lewy body-injected mice and monkeys did not appear to accumulate typical Lewy body-type aggregates but instead showed phosphorylated alpha-synuclein that adopted a more punctate, inclusion-like conformation. Importantly, unlike brain homogenates from mice injected with PBS, brain homogenates from mice injected with MSA and iLBD patient brain extracts were able to seed alpha-synuclein aggregation in vitro as determined by ThT binding assays, suggesting that these mouse brains contained abnormal misfolded alpha-synuclein that was seeding competent. Variation in the ThT fluorescence signal between the different samples may be attributable to stochastic sampling effects or possibly to a heterogeneous population of abnormal alpha-synuclein species in the homogenates. A limitation of ThT binding assay may be that it could detect residual seeds originating form the injected patient material. Considering that the histology results are negative for phosphorylated alpha-synuclein at 3 months post injection and only become positive at 6 months post injection for animals injected with patient brain extracts, this assay likely detects de novo generated seeds.
In contrast to PD and DLB, where aggregates of alpha-synuclein are mostly found in neurons, inclusions of misfolded alpha-synuclein in MSA have been mostly associated with oligodendrocytes in the past. A recent study however shows that in addition to glial inclusions also neuronal inclusions of alpha-synuclein are widespread and play an important role in the development and progression of MSA . Interestingly, another study reported that the structural conformation (strain) of the injected alpha-synuclein aggregates, in this case fibrils versus ribbons, was found to induce alpha-synuclein inclusions only in neurons, as observed in PD, or in neurons and oligodendrocytes, as observed for MSA . The latter, however, was observed only after combined rAAV-mediated alpha-synuclein overexpression with alpha-synuclein ribbons inoculation, which led to a second but sparse alpha-synuclein phosphorylation in oligodendrocytes.
In this study, brain extracts of MSA patients caused accumulation of phosphorylated alpha-synuclein mostly in neurons and rarely in oligodendrocytes of Tg(SNCA)1Nbm/J mice. With regard to observations in M20-mice injected with alpha-synuclein fibrils, we detected phosphorylated alpha-synuclein aggregates only occasionally in astrocytes and microglia (Additional file 4) , which may explain the lack of wide spread gliosis in our model system (Additional files 6 and 7). A lack of oligodendroglial accumulation of phosphorylated alpha-synuclein has also been observed in M83+/−-mice injected with brain homogenates from MSA patients and it was speculated that the lack of alpha-synuclein aggregation in oligodendrocytes might be due to poor transgene expression in these cells [39, 61]. Low expression levels of alpha-synuclein in oligodendrocytes may not support prion-like seeding and accumulation of alpha-synuclein after transfer from neurons . Expression of alpha-synuclein in M20- and M83-mice are driven from the prion promoter, while expression of human alpha-synuclein in Tg(SNCA)1Nbm/J mice is driven from a P1 artificial chromosome, which contains the human promoter for alpha-synuclein. Although human oligodendrocytes were long thought not to express alpha-synuclein, a recent study revealed that the expression of alpha-synuclein in MSA neurons and glial cells is enhanced [1, 32]. Thus, the lack of alpha-synuclein pathology in oligodendrocytes of Tg(SNCA)1Nbm/J mice might be due to missing enhancer elements in the P1 artificial chromosome or to the lack of a yet unresolved mechanism in trans, governing the expression of alpha-synuclein in MSA. Our data does not argue for or against the existence of strains with regard to misfolded alpha-synuclein species and emphasize the necessity for additional studies to understand this matter in greater detail.
ILBD is a prodromal form of synucleinopathy, e.g. PD or DLB, that has not resulted in dementia or parkinsonism yet, and is found in 8-17 % of neurologically asymptomatic individuals over the age of 60 on post-mortem examination [7, 9, 10, 13, 16]. Cortical brain extracts from the two probable iLBD cases investigated here caused a similar spatiotemporally progressive synucleinopathy in Tg(SNCA)1Nbm/J mice as those from the two MSA patients, which lets us conclude that they were indeed true iLBD cases. Moreover, several other transmission studies to animal models in the past have shown that a positive transmission result is not to be expected in the absence of alpha-synuclein aggregates in the injected material as it is observed after injection with PBS [28, 29, 31, 47, 61]. The concentration of alpha-synuclein in the sarkosyl-insoluble fraction of the iLBD2 sample was slightly lower than in the other brain extracts (Table 1). Titration experiments in prion transmission studies show that only large differences in titers that can span several tenfold dilutions lead to large differences in the incubation time in inoculated animals [38, 54, 55]. We injected Tg(SNCA)Nbm1/J mice with a high dose of misfolded alpha-synuclein species from the sarkosyl-insoluble fraction of MSA and iLBD brains and did not observe any difference in the spatiotemporal expansion of alpha-synuclein pathology in the brains of injected mice. Only more comprehensive titration studies in mice with sarkosyl-insoluble fractions from brain extracts of patients with synucleinopathies will show at which concentrations of alpha-synuclein differences in the spread of this pathology becomes observable. Our findings argue that the pathologic alpha-synuclein species in the brains of patients with iLBD are comparable to those from MSA brains in their ability to induce pathology in Tg(SNCA)1Nbm/J mice.
We show that human wild-type alpha-synuclein by itself, in the absence of endogenously expressed mouse alpha-synuclein, supports a prion-like mechanism in the spreading of pathological alpha-synuclein, which does not necessitate the presence of fulminant Lewy body-type pathology. In our experiments sarkosyl-soluble pathogenic alpha-synuclein species, which need to be further characterized, were readily transmitted between neurons supporting the concept that the appearance of additional detergent-insoluble alpha-synuclein species and Lewy body pathology may represent a late cellular event in mature synucleinopathies [19, 34, 41]. Consequentially, potential therapeutic strategies targeting the interneuronal spread of soluble pathogenic alpha-synuclein in synucleinopathies such as PD or MSA may be promising but effective only early in the disease process.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
We thank Mrs. Olga Sharma and Mrs. Theresa Hundt for excellent technical assistance and the staff of the DZNE animal facility for support with animal experiments. We thank Dr. Sybille Kraus, Dr. Walker Jackson, and Dr. Kurt Jellinger for careful review of this manuscript. We thank Donato A. Di Monte und Ayse Ulusoy for helpful discussions. We thank the DZNE microscopy and animal facilities for technical support. We thank the Brain Banking Centers Leipzig, Münster, and Tübingen, and the Queen Square Brain Bank for Neurological Disorders for contributing tissue samples for this study.
This study was funded by the German Research Center for Neurodegenerative Diseases (DZNE).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Asi YT, Simpson JE, Heath PR, Wharton SB, Lees AJ, Revesz T, et al. Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia. 2014;62:964–70. doi:10.1002/glia.22653.PubMed CentralView ArticlePubMedGoogle Scholar
- Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, et al. Current Protocols in Molecular Biology. New York: John Wiley & Sons; 1989.Google Scholar
- Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197–211. doi:10.1016/S0197-4580(02)00065-9.View ArticlePubMedGoogle Scholar
- Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004;364:1167–9. doi:10.1016/S0140-6736(04)17103-1.View ArticlePubMedGoogle Scholar
- Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Sci. 2007;318:930–6. doi:10.1126/science.1138718.View ArticleGoogle Scholar
- Cykowski MD, Coon EA, Powell SZ, Jenkins SM, Benarroch EE, Low PA, et al. Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain. 2015;138:2293–309. doi:10.1093/brain/awv114.View ArticlePubMedGoogle Scholar
- DelleDonne A, Klos KJ, Fujishiro H, Ahmed Z, Parisi JE, Josephs KA, et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol. 2008;65:1074–80. doi:10.1001/archneur.65.8.1074.View ArticlePubMedGoogle Scholar
- Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009;106:13010–5. doi:10.1073/pnas.0903691106.PubMed CentralView ArticlePubMedGoogle Scholar
- Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. 2008;115:437–44. doi:10.1007/s00401-008-0345-7.View ArticlePubMedGoogle Scholar
- Frigerio R, Fujishiro H, Ahn TB, Josephs KA, Maraganore DM, DelleDonne A, et al. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiology of aging. 2011;32:857–63. doi:10.1016/j.neurobiolaging.2009.05.019.PubMed CentralView ArticlePubMedGoogle Scholar
- Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160–4. doi:10.1038/ncb748.View ArticlePubMedGoogle Scholar
- Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002;34:521–33. doi:10.1016/S0896-6273(02)00682-7.View ArticlePubMedGoogle Scholar
- Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51:745–52.PubMed CentralView ArticlePubMedGoogle Scholar
- Gispert S, Del Turco D, Garrett L, Chen A, Bernard DJ, Hamm-Clement J, et al. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci. 2003;24:419–29. doi:10.1016/S1044-7431(03)00198-2.View ArticlePubMedGoogle Scholar
- Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet. 2004;364:1169–71. doi:10.1016/S0140-6736(04)17104-3.View ArticlePubMedGoogle Scholar
- Iranzo A, Gelpi E, Tolosa E, Molinuevo JL, Serradell M, Gaig C, et al. Neuropathology of prodromal Lewy body disease. Mov Disord. 2014;29:410–5. doi:10.1002/mds.25825.View ArticlePubMedGoogle Scholar
- Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008;14:504–6. doi:10.1038/nm1747.View ArticlePubMedGoogle Scholar
- Kovacs GG, Breydo L, Green R, Kis V, Puska G, Lorincz P, et al. Intracellular processing of disease-associated alpha-synuclein in the human brain suggests prion-like cell-to-cell spread. Neurobiol Dis. 2014;69:76–92. doi:10.1016/j.nbd.2014.05.020.View ArticlePubMedGoogle Scholar
- Kramer ML, Schulz-Schaeffer WJ (2007) Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 27: 1405–1410. doi:10.1523/JNEUROSCI.4564-06.2007
- Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998;18:106–8. doi:10.1038/ng0298-106.View ArticlePubMedGoogle Scholar
- Kuo YM, Li Z, Jiao Y, Gaborit N, Pani AK, Orrison BM, et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet. 2010;19:1633–50. doi:10.1093/hmg/ddq038.PubMed CentralView ArticlePubMedGoogle Scholar
- Kuusisto E, Salminen A, Alafuzoff I. Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport. 2001;12:2085–90.View ArticlePubMedGoogle Scholar
- Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, Ihara Y. Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol. 1988;75:345–53.View ArticlePubMedGoogle Scholar
- Lamberts JT, Hildebrandt EN, Brundin P. Spreading of alpha-synuclein in the face of axonal transport deficits in Parkinson's disease: a speculative synthesis. Neurobiol Dis. 2015;77:276–83. doi:10.1016/j.nbd.2014.07.002.View ArticlePubMedGoogle Scholar
- Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med. 2008;14:501–3. doi:10.1038/nm1746.View ArticlePubMedGoogle Scholar
- Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billett M, et al. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J Pathol. 1988;155:9–15. doi:10.1002/path.1711550105.View ArticlePubMedGoogle Scholar
- Lue LF, Walker DG, Adler CH, Shill H, Tran H, Akiyama H, et al. Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol. 2012;22:745–56. doi:10.1111/j.1750-3639.2012.00585.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Sci. 2012;338:949–53. doi:10.1126/science.1227157.View ArticleGoogle Scholar
- Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med. 2012;209:975–86. doi:10.1084/jem.20112457.PubMed CentralView ArticlePubMedGoogle Scholar
- Masuda-Suzukake M, Nonaka T, Hosokawa M, Kubo M, Shimozawa A, Akiyama H, Hasegawa M (2014) Pathological alpha-synuclein propagates through neural networks. Acta neuropathologica communications 2: 88. doi:10.1186/PREACCEPT-1296467154135944
- Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, et al. Prion-like spreading of pathological alpha-synuclein in brain. Brain. 2013;136:1128–38. doi:10.1093/brain/awt037.PubMed CentralView ArticlePubMedGoogle Scholar
- Miller DW, Johnson JM, Solano SM, Hollingsworth ZR, Standaert DG, Young AB. Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm. 2005;112:1613–24. doi:10.1007/s00702-005-0378-1.View ArticlePubMedGoogle Scholar
- Mougenot AL, Nicot S, Bencsik A, Morignat E, Verchere J, Lakhdar L, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging. 2012;33:2225–8. doi:10.1016/j.neurobiolaging.2011.06.022.View ArticlePubMedGoogle Scholar
- Osterberg VR, Spinelli KJ, Weston LJ, Luk KC, Woltjer RL, Unni VK. Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of parkinsonism. Cell Rep. 2015;10:1252–60. doi:10.1016/j.celrep.2015.01.060.View ArticlePubMedGoogle Scholar
- Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol. 2005;57:82–91. doi:10.1002/ana.20321.View ArticlePubMedGoogle Scholar
- Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M, et al. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522:340–4. doi:10.1038/nature14547.View ArticlePubMedGoogle Scholar
- Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Sci. 1997;276:2045–7. doi:10.1126/science.276.5321.2045.View ArticleGoogle Scholar
- Prusiner SB, Cochran SP, Groth DF, Downey DE, Bowman KA, Martinez HM. Measurement of the scrapie agent using an incubation time interval assay. Ann Neurol. 1982;11:353–8. doi:10.1002/ana.410110406.View ArticlePubMedGoogle Scholar
- Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB, et al. Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A. 2015.doi:10.1073/pnas.1514475112
- Recasens A, Dehay B, Bove J, Carballo-Carbajal I, Dovero S, Perez-Villalba A, et al. Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol. 2014;75:351–62. doi:10.1002/ana.24066.View ArticlePubMedGoogle Scholar
- Rey NL, Petit GH, Bousset L, Melki R, Brundin P. Transfer of human alpha-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol. 2013;126:555–73. doi:10.1007/s00401-013-1160-3.PubMed CentralView ArticlePubMedGoogle Scholar
- Reyes JF, Olsson TT, Lamberts JT, Devine MJ, Kunath T, Brundin P. A cell culture model for monitoring alpha-synuclein cell-to-cell transfer. Neurobiol Dis. 2015;77:266–75. doi:10.1016/j.nbd.2014.07.003.View ArticlePubMedGoogle Scholar
- Reyes JF, Rey NL, Bousset L, Melki R, Brundin P, Angot E. Alpha-synuclein transfers from neurons to oligodendrocytes. Glia. 2014;62:387–98. doi:10.1002/glia.22611.View ArticlePubMedGoogle Scholar
- Rochet JC, Conway KA, Lansbury Jr PT. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochem. 2000;39:10619–26. doi:10.1021/bi001315u.View ArticleGoogle Scholar
- Sacino AN, Brooks M, McGarvey NH, McKinney AB, Thomas MA, Levites Y, et al. Induction of CNS alpha-synuclein pathology by fibrillar and non-amyloidogenic recombinant alpha-synuclein. Acta Neuropathologica Communications. 2013;1:38. doi:10.1186/2051-5960-1-38.PubMed CentralView ArticlePubMedGoogle Scholar
- Sacino AN, Brooks M, McKinney AB, Thomas MA, Shaw G, Golde TE, et al. Brain injection of alpha-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker. J Neurosci. 2014;34:12368–78. doi:10.1523/JNEUROSCI.2102-14.2014.View ArticlePubMedGoogle Scholar
- Sacino AN, Brooks M, Thomas MA, McKinney AB, Lee S, Regenhardt RW, et al. Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci U S A. 2014;111:10732–7. doi:10.1073/pnas.1321785111.PubMed CentralView ArticlePubMedGoogle Scholar
- Sacino AN, Brooks M, Thomas MA, McKinney AB, McGarvey NH, Rutherford NJ, et al. Amyloidogenic alpha-synuclein seeds do not invariably induce rapid, widespread pathology in mice. Acta Neuropathol. 2014;127:645–65. doi:10.1007/s00401-014-1268-0.View ArticlePubMedGoogle Scholar
- Schmid AW, Fauvet B, Moniatte M, Lashuel HA. Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol Cell Proteomics. 2013;12:3543–58. doi:10.1074/mcp.R113.032730.PubMed CentralView ArticlePubMedGoogle Scholar
- Scott M, Foster D, Mirenda C, Serban D, Coufal F, Walchli M, et al. Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell. 1989;59:847–57.View ArticlePubMedGoogle Scholar
- Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841. doi:10.1126/science.1090278
- Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett. 1998;251:205–8.View ArticlePubMedGoogle Scholar
- Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A. 1998;95:6469–73.PubMed CentralView ArticlePubMedGoogle Scholar
- Tamgüney G, Francis KP, Giles K, Lemus A, DeArmond SJ, Prusiner SB. Measuring prions by bioluminescence imaging. Proc Natl Acad Sci U S A. 2009;106:15002–6. doi:10.1073/pnas.0907339106.PubMed CentralView ArticlePubMedGoogle Scholar
- Tamgüney G, Miller MW, Wolfe LL, Sirochman TM, Glidden DV, Palmer C, et al. Asymptomatic deer excrete infectious prions in faeces. Nature. 2009;461:529–32. doi:10.1038/nature08289.PubMed CentralView ArticlePubMedGoogle Scholar
- Telling GC, Scott M, Hsiao KK, Foster D, Yang SL, Torchia M, et al. Transmission of Creutzfeldt-Jakob disease from humans to transgenic mice expressing chimeric human-mouse prion protein. Proc Natl Acad Sci U S A. 1994;91:9936–40.PubMed CentralView ArticlePubMedGoogle Scholar
- Telling GC, Scott M, Mastrianni J, Gabizon R, Torchia M, Cohen FE, et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell. 1995;83:79–90.View ArticlePubMedGoogle Scholar
- Ulusoy A, Rusconi R, Perez-Revuelta BI, Musgrove RE, Helwig M, Winzen-Reichert B, et al. Caudo-rostral brain spreading of alpha-synuclein through vagal connections. EMBO Mol Med. 2013;5:1051–9. doi:10.1002/emmm.201302475.PubMed CentralView ArticlePubMedGoogle Scholar
- Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72:57–71. doi:10.1016/j.neuron.2011.08.033.PubMed CentralView ArticlePubMedGoogle Scholar
- Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett. 1998;249:180–2.View ArticlePubMedGoogle Scholar
- Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, Gentleman SM, et al. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci U S A. 2013;110:19555–60. doi:10.1073/pnas.1318268110.PubMed CentralView ArticlePubMedGoogle Scholar
- Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55:164–73. doi:10.1002/ana.10795.View ArticlePubMedGoogle Scholar